Jonathan Charles Alexander Skipper
Direktor/Vorstandsmitglied bei Cancer Vaccine Acceleration Co. LLC
Profil
Jonathan Charles Alexander Skipper is currently the Executive Director-Technology Development at Ludwig Institute for Cancer Research Ltd.
He also holds director positions at Cancer Vaccine Acceleration Co. LLC, Recepta Biopharma SA, Seramtrix, Inc., iTeos Therapeutics SA, and iOX Therapeutics Ltd.
Previously, he served as a Non-Executive Director at Opthea Ltd.
from 2008 to 2011 and held a director position at Vegenics Pty Ltd.
Dr. Skipper obtained a doctorate degree from University College London.
Aktive Positionen von Jonathan Charles Alexander Skipper
Unternehmen | Position | Beginn |
---|---|---|
Ludwig Institute for Cancer Research Ltd.
Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Cancer Vaccine Acceleration Co. LLC
Cancer Vaccine Acceleration Co. LLC Financial ConglomeratesFinance Part of Cancer Research Institute, Cancer Vaccine Acceleration Co. LLC is an alternative investment manager. The company is based in New York, NY. | Direktor/Vorstandsmitglied | - |
Recepta Biopharma SA
Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | Direktor/Vorstandsmitglied | - |
Seramtrix, Inc. | Direktor/Vorstandsmitglied | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Direktor/Vorstandsmitglied | - |
iOX Therapeutics Ltd.
iOX Therapeutics Ltd. BiotechnologyHealth Technology iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 01.07.2015 |
Ehemalige bekannte Positionen von Jonathan Charles Alexander Skipper
Unternehmen | Position | Ende |
---|---|---|
OPTHEA LIMITED | Direktor/Vorstandsmitglied | 24.11.2011 |
Vegenics Pty Ltd.
Vegenics Pty Ltd. Medical/Nursing ServicesHealth Services Part of Opthea Ltd., Vegenics Pty Ltd. is an Australian company that provides medical research, development, and commercialization of biologic drugs. Vegenics was acquired by Opthea Ltd. on August 14, 2008 for $5.06 million. | Corporate Officer/Principal | - |
Ausbildung von Jonathan Charles Alexander Skipper
University College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
OPTHEA LIMITED | Health Technology |
Private Unternehmen | 7 |
---|---|
Ludwig Institute for Cancer Research Ltd.
Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Health Services |
Vegenics Pty Ltd.
Vegenics Pty Ltd. Medical/Nursing ServicesHealth Services Part of Opthea Ltd., Vegenics Pty Ltd. is an Australian company that provides medical research, development, and commercialization of biologic drugs. Vegenics was acquired by Opthea Ltd. on August 14, 2008 for $5.06 million. | Health Services |
Cancer Vaccine Acceleration Co. LLC
Cancer Vaccine Acceleration Co. LLC Financial ConglomeratesFinance Part of Cancer Research Institute, Cancer Vaccine Acceleration Co. LLC is an alternative investment manager. The company is based in New York, NY. | Finance |
Recepta Biopharma SA
Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | Health Technology |
Seramtrix, Inc. | |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
iOX Therapeutics Ltd.
iOX Therapeutics Ltd. BiotechnologyHealth Technology iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom. | Health Technology |